New hope for kids with rare epilepsy: drug trial targets seizures

NCT ID NCT05818553

First seen Feb 01, 2026 · Last updated May 16, 2026 · Updated 12 times

Summary

This study tests an experimental drug called PRAX-562 in 77 children with rare genetic epilepsies (SCN2A or SCN8A) that cause severe seizures starting in infancy. The goal is to see if the drug is safe and can reduce monthly motor seizures. The trial has a double-blind phase followed by an open-label extension where all children receive the drug.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCN2A ENCEPHALOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Praxis Research Site

    Atlanta, Georgia, 30329, United States

  • Praxis Research Site

    Chicago, Illinois, 60611, United States

  • Praxis Research Site

    Minneapolis, Minnesota, 55113, United States

  • Praxis Research Site

    Hackensack, New Jersey, 07601, United States

  • Praxis Research Site

    Tel Litwinsky, 52621, Israel

  • Praxis Research Site

    Madrid, 28034, Spain

  • Praxis Research Site

    Glasgow, G51 4TF, United Kingdom

  • Praxis Research Site

    London, WC1N 3BH, United Kingdom

Conditions

Explore the condition pages connected to this study.